An article in the New England Journal of Medicine discusses the use of beta-blockers after myocardial infarction to guide personalized management. The REDUCE-AMI study randomized 5,000 patients with normal left ventricular ejection fraction after revascularization to beta-blockers (metoprolol or bisoprolol) or no beta-blockers. After a mean follow-up of 3.5 years, the combined rate of death or another heart attack was 4% lower in the beta-blocker group, but this was not statistically significant.[1][2] The French ABYSS study of 3700 post-heart attack patients showed that discontinuation of beta-blockers led to a higher frequency of cardiovascular hospitalizations (17% vs. 21%).[2][6][7] Beta-blockers are of unquestionable benefit in patients with signs of heart failure or left ventricular dysfunction.[3] In the era of revascularization and modern treatment, their overall benefit in low-risk patients with preserved ejection fraction is smaller.[1][2][4] These findings support the adaptation of treatment to the individual profile of the patient.[1]